CJC/IPA Blend 10mg

CJC/IPA Blend 10mg is a meticulously formulated, research-grade dual growth hormone secretagogue peptide blend that elegantly combines two of the most extensively studied, scientifically celebrated, and complementary growth hormone-releasing research peptides in contemporary endocrinological and metabolic science — CJC-1295 (without DAC) and Ipamorelin — into a single, precisely co-formulated lyophilized research vial. Representing one of the most scientifically well-conceived and strategically designed dual-peptide research formulations available in the Mile High Compounds product lineup, the CJC/IPA Blend embodies a sophisticated understanding of the complementary and synergistic nature of GHRH receptor agonism and ghrelin receptor activation as dual, interconnected pathways for investigating growth hormone axis biology and somatotropic signaling regulation.

The scientific brilliance of the CJC/IPA Blend formulation lies in its precise targeting of two distinct but deeply interconnected receptor systems that collectively govern the pituitary gland's growth hormone secretory activity. CJC-1295 (without DAC), a stabilized synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH), engages the GHRH receptor on pituitary somatotroph cells, stimulating growth hormone synthesis and triggering the physiologically consistent, pulsatile pattern of growth hormone release that closely mirrors the body's natural endogenous GHRH activity. Ipamorelin, a highly selective synthetic pentapeptide and ghrelin receptor (GHS-R1a) agonist, simultaneously engages an entirely different receptor pathway to potentiate growth hormone release through a complementary and mechanistically distinct signaling cascade — creating a dual-receptor research framework of exceptional scientific depth, biological relevance, and investigative power.

What makes the combination of CJC-1295 (without DAC) and Ipamorelin particularly compelling from a scientific research perspective is the well-recognized mechanistic complementarity and potential synergism between GHRH receptor agonism and ghrelin receptor activation in the regulation of pituitary growth hormone secretion. Research has consistently demonstrated that simultaneous engagement of both receptor pathways produces a more robust and physiologically comprehensive growth hormone secretory response than activation of either pathway in isolation — making the CJC/IPA Blend an extraordinarily powerful research tool for scientists seeking to investigate the full complexity of growth hormone axis regulation, dual-receptor somatotropic signaling, and the downstream metabolic consequences of enhanced growth hormone secretory activity in controlled in vitro research environments.

The 10mg total blend volume — comprising precisely 5mg of CJC-1295 (without DAC) and 5mg of Ipamorelin in a single lyophilized vial — provides research teams with a well-balanced, practical, and scientifically meaningful compound supply for structured laboratory investigations, comparative endocrinological research protocols, and comprehensive growth hormone axis biology studies requiring consistent compound availability, precise formulation integrity, and the highest standards of lyophilization quality and experimental reproducibility.

Blend Composition & Individual Component Profiles:

① CJC-1295 (without DAC) — 5mg (Growth Hormone Releasing Hormone Analogue) CJC-1295 without DAC — also known in research literature as Modified GRF (1-29) or Mod GRF 1-29 — is a precisely engineered synthetic analogue of the first 29 amino acids of endogenous Growth Hormone Releasing Hormone, incorporating four strategic amino acid substitutions that significantly enhance the peptide's biological stability, receptor binding affinity, and resistance to enzymatic degradation compared to the native GHRH (1-29) sequence. Without the Drug Affinity Complex (DAC) modification present in its longer-acting counterpart, CJC-1295 without DAC retains a pharmacokinetic profile that more closely mirrors the natural pulsatile pattern of endogenous GHRH activity — making it the ideal GHRH analogue for research protocols designed to investigate physiologically relevant, pulsatile growth hormone secretion dynamics and GHRH receptor signaling biology.

② Ipamorelin — 5mg (Selective Ghrelin Receptor Agonist / Growth Hormone Secretagogue) Ipamorelin is a highly selective, third-generation synthetic pentapeptide growth hormone secretagogue that acts as a potent and exceptionally specific agonist at the ghrelin receptor (GHS-R1a) — the primary receptor mediating ghrelin-induced growth hormone release from pituitary somatotroph cells. What distinguishes Ipamorelin from earlier generation growth hormone secretagogues such as GHRP-2 and GHRP-6 is its remarkable receptor selectivity profile — demonstrating highly specific GHS-R1a activation with minimal influence on cortisol, prolactin, and ACTH secretion compared to its predecessors. This exceptional selectivity makes Ipamorelin one of the most scientifically valuable and research-relevant ghrelin receptor agonists available, providing researchers with a clean, interpretable, and highly specific tool for investigating ghrelin receptor biology and GHS-R1a-mediated growth hormone secretory mechanisms in controlled laboratory research settings.

Research Applications:

The CJC/IPA Blend 10mg supports an exceptionally comprehensive and scientifically rich range of research applications spanning endocrinology, growth hormone axis biology, metabolic science, cellular biochemistry, and systems-level somatotropic signaling research, including:

• Dual-Receptor Growth Hormone Axis Research — conducting comprehensive investigations into the combined and potentially synergistic influence of simultaneous GHRH receptor and ghrelin receptor activation on pituitary somatotroph cell biology, growth hormone synthesis regulation, and the systems-level coordination of dual-pathway somatotropic signaling in controlled in vitro research models

• GHRH Receptor Signaling & Somatotroph Biology Research — examining CJC-1295 (without DAC)'s highly selective influence on GHRH receptor binding dynamics, intracellular cAMP accumulation, PKA pathway activation, and somatotroph cell stimulation, investigating how GHRH receptor-mediated signaling contributes to the regulation of growth hormone synthesis and pulsatile release patterns in laboratory research settings

• Ghrelin Receptor Biology & GHS-R1a Signaling Research — studying Ipamorelin's exceptional receptor selectivity and its influence on GHS-R1a binding kinetics, intracellular calcium mobilization, phospholipase C pathway activation, and the downstream consequences of highly selective ghrelin receptor agonism on growth hormone secretory mechanisms and somatotroph cell biology in controlled research environments

• IGF-1 Axis & Downstream Metabolic Signaling Research — investigating the downstream consequences of dual-pathway growth hormone secretagogue activity on hepatic IGF-1 production, IGF-1 receptor signaling cascades, and the broad spectrum of anabolic, metabolic, and tissue biology processes regulated by the GH/IGF-1 axis in controlled in vitro research frameworks

• Pulsatile Growth Hormone Secretion Research — exploring CJC-1295 (without DAC)'s unique ability to stimulate physiologically relevant pulsatile growth hormone release patterns within the CJC/IPA Blend framework, examining how GHRH receptor-mediated pulsatile secretion dynamics interact with Ipamorelin's ghrelin receptor-mediated secretagogue activity to influence the temporal pattern, amplitude, and frequency characteristics of growth hormone secretory responses in laboratory research models

• Receptor Selectivity & Specificity Research — utilizing Ipamorelin's exceptional GHS-R1a selectivity profile within the CJC/IPA Blend formulation to conduct detailed receptor specificity studies, examining the differential consequences of highly selective versus non-selective ghrelin receptor activation on somatotroph cell biology, growth hormone secretory dynamics, and associated endocrine signaling networks in controlled research settings

• Metabolic Regulation & Energy Homeostasis Research — studying the collective influence of the CJC/IPA Blend's dual growth hormone secretagogue activity on metabolic regulation, energy substrate utilization, lipid metabolism, glucose homeostasis, and the systemic metabolic consequences of enhanced growth hormone axis activation through simultaneous dual-receptor engagement in laboratory research models

• Body Composition & Lean Tissue Biology Research — investigating the relationship between dual-pathway growth hormone secretagogue activity and lean tissue biology, examining how combined GHRH receptor and ghrelin receptor activation influences muscle protein synthesis signaling, satellite cell biology, adipose tissue metabolism, and the cellular determinants of body composition regulation in controlled in vitro research frameworks

• Bone Biology & Skeletal Research — exploring the influence of CJC/IPA Blend-mediated growth hormone axis activation on osteoblast biology, bone matrix synthesis regulation, and the cellular mechanisms governing skeletal tissue maintenance and remodeling, examining how dual-pathway growth hormone secretagogue activity influences the GH/IGF-1 axis's well-documented role in bone biology research

• Comparative Growth Hormone Secretagogue Research — utilizing the CJC/IPA Blend alongside individual component compounds and alternative growth hormone secretagogue combinations in comparative research frameworks designed to characterize the relative potency, receptor selectivity, and biological activity profiles of different dual-receptor versus single-receptor growth hormone secretagogue research approaches

• Synergistic Dual-Peptide Endocrinology Research — employing the CJC/IPA Blend as a purpose-built research tool for investigating the fundamental scientific question of whether simultaneous GHRH receptor and ghrelin receptor co-activation produces synergistic growth hormone secretory responses that exceed the sum of individual pathway contributions, advancing the scientific understanding of inter-receptor crosstalk and cooperative signaling dynamics in pituitary somatotroph cell biology

• Pharmacokinetic & Receptor Binding Profiling Research — conducting detailed pharmacokinetic characterization studies, receptor binding affinity measurements, and dose-response relationship investigations for both CJC-1295 (without DAC) and Ipamorelin within the combined blend formulation, examining how co-administration of two distinct growth hormone secretagogue peptides influences the individual pharmacokinetic and receptor binding profiles of each component compound

Specifications:

Intended Use: This compound is intended strictly for in vitro laboratory research. It is not approved for human or animal consumption and must not be incorporated into food, drugs, supplements, or cosmetics.

Legal Disclaimer: This product and all related information have not been evaluated by the U.S. Food and Drug Administration. No claims are made regarding diagnosis, treatment, cure, or prevention of disease. Use is limited to qualified research professionals in certified laboratory environments.

Terms of Sale: By purchasing from Mile High Compounds, the buyer affirms they are a qualified researcher or institution. The purchaser assumes full responsibility for lawful handling, storage, and application of this material. All sales are final.